MorphoSys AG said it was "disappointed" about a US court ruling against the German biotech in its three-year patent dispute with Danish biotech Genmab AS and pharma giant Johnson & Johnson over blood cancer blockbuster Darzalex (daratumumab). The ruling has blocked the start of a jury trial.
The complaint, filed in 2016 by MorphoSys with the US District Court of Delaware, alleges that Darzalex, an antibody-based biologic...








